MedPath

HK inno.N Corporation

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Chronic Idiopathic Constipation
Interventions
Drug: IN-114199 10mg or placebo
Drug: IN-114199 20mg or placebo
Drug: IN-114199 2.5mg or placebo
Drug: IN-114199 5mg or placebo
Drug: IN-114199 40mg or placebo
First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
80
Registration Number
NCT06736912
Locations
🇰🇷

Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers

Phase 1
Active, not recruiting
Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
Drug: IN-G00002
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
60
Registration Number
NCT06725355
Locations
🇰🇷

Central Hospital, Clinical Trial Center, Siheung, Korea, Republic of

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Recruiting
Conditions
Adjuvant Chemotherapy
First Posted Date
2024-04-29
Last Posted Date
2024-04-29
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
36
Registration Number
NCT06389552
Locations
🇰🇷

Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

First Posted Date
2024-03-27
Last Posted Date
2024-03-27
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
36
Registration Number
NCT06332638
Locations
🇰🇷

Inje University Busan Paik Hospital, Busan, Korea, Republic of

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Phase 1
Not yet recruiting
Conditions
Healthy
Interventions
First Posted Date
2023-12-11
Last Posted Date
2023-12-11
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
48
Registration Number
NCT06164834
Locations
🇰🇷

Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
381
Registration Number
NCT05933031
Locations
🇰🇷

Chung-Ang University Hosptial, Seoul, Korea, Republic of

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Phase 1
Not yet recruiting
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 3%
Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 1%
First Posted Date
2023-02-15
Last Posted Date
2023-02-15
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
80
Registration Number
NCT05729074

PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

First Posted Date
2023-02-10
Last Posted Date
2023-12-11
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
87
Registration Number
NCT05723510
Locations
🇰🇷

Jeonbuk National University Hospital, Jeonju, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Phase 4
Recruiting
Conditions
Gastroesophageal Reflux Disease
Interventions
First Posted Date
2023-01-27
Last Posted Date
2023-08-03
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
338
Registration Number
NCT05701540
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers

Phase 1
Conditions
Healthy
Interventions
First Posted Date
2022-04-29
Last Posted Date
2022-04-29
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
12
Registration Number
NCT05353010
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath